SKSandhya Krishnan

Sandhya Krishnan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sandhya Krishnan has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma

    by Salah-Eddine Lamhamedi-Cherradi, Mayinuer Maitituoheti, Brian A. Menegaz, Sandhya Krishnan, Amelia M. Vetter, Pamela Camacho, Chia-Chin Wu, Hannah C. Beird, Robert W. Porter, Davis R. Ingram, et al.

    Desmoplastic small round cell tumor (DSRCT) is an aggressive, usually incurable sarcoma subtype that predominantly occurs in post-pubertal young males. Recent evidence suggests that the androgen receptor (AR) can promote tumor progression in DSRCTs. However, the mechanism of AR-induced oncogenic stimulation remains undetermined. Herein, we demonstrate that enzalutamide and AR-directed antisense oligonucleotides (AR-ASO) block 5α-dihydrotestosterone (DHT)-induced DSRCT cell proliferation and reduce xenograft tumor burden. Gene expression analysis and chromatin immunoprecipitation sequencing (ChIP-seq) were performed to elucidate how AR signaling regulates cellular epigenetic programs. Remarkably, ChIP-seq revealed novel DSRCT-specific AR DNA binding sites adjacent to key oncogenic regulators, including WT1 (the C-terminal partner of the pathognomonic fusion protein) and FOXF1. Additionally, AR occupied enhancer sites that regulate the Wnt pathway, neural differentiation, and embryonic organ development, implicating AR in dysfunctional cell lineage commitment. Our findings have direct clinical implications given the widespread availability of FDA-approved androgen-targeted agents used for prostate cancer.


  • Open Access

    Dissociation Protocols used for Sarcoma Tissues Bias the Transcriptome observed in Single-cell and Single-nucleus RNA sequencing

    by Danh D. Truong, Salah-Eddine Lamhamedi-Cherradi, Robert W. Porter, Sandhya Krishnan, Jyothishmathi Swaminathan, Amber L. Gibson, Alexander J. Lazar, John A. Livingston, Vidya Gopalakrishnan, Nancy Gordon, et al.

    Background Single-cell RNA-seq has emerged as an innovative technology used to study complex tissues and characterize cell types, states, and lineages at a single-cell level. Rapid adoption of this technology has led to a flurry of research creating single-cell atlases for many organs, cancers, and developmental models. Despite the tremendous success of this technology, sarcomas, rare cancers of mesenchymal origin, have not yet widely benefited from the adoption of single-cell RNA-seq. Due to their rarity, obtaining fresh clinical specimens is challenging. Single-nucleus RNA-seq could remove limitations from obtaining fresh tissue and enable immediate processing of archival tissue. However, biases may exist during dissociation of either fresh or frozen specimens that can hinder reproducible results and introduce technical or biological artifacts. Results To address these questions, we systematically assessed dissociation methods across different sarcoma subtypes. Here, we compare gene expression from single-cell and single-nucleus RNA-sequencing of 125,831 whole-cells and nuclei from Ewing’s sarcoma, desmoplastic small round cell tumor, and osteosarcoma patient-derived xenografts. We detected warm dissociation artifacts from single-cell samples and gene length bias in single-nucleus samples. Classic sarcoma gene signatures were observed regardless of dissociation method. Finally, we show that dissociation method biases can be computationally corrected. Conclusions We highlighted transcriptional biases, including warm dissociation and gene-length biases, introduced by any dissociation method for various sarcoma subtypes. This work will inform researchers on choice of dissociation method and careful interpretation of data due to dissociation biases.


  • Open Access

    Transcriptional activators YAP/TAZ and AXL orchestrate dedifferentiation, cell fate, and metastasis in human osteosarcoma

    by Salah-Eddine Lamhamedi-Cherradi, Sana Mohiuddin, Dhruva K. Mishra, Sandhya Krishnan, Alejandra Ruiz Velasco, Amelia M. Vetter, Kristi Pence, David McCall, Danh D. Truong, Branko Cuglievan, et al.

    Osteosarcoma (OS) is a molecularly heterogeneous, aggressive, poorly differentiated pediatric bone cancer that frequently spreads to the lung. Relatively little is known about phenotypic and epigenetic changes that promote lung metastases. To identify key drivers of metastasis, we studied human CCH-OS-D OS cells within a previously described rat acellular lung (ACL) model that preserves the native lung architecture, extracellular matrix, and capillary network. This system identified a subset of cells—termed derived circulating tumor cells (dCTCs)—that can migrate, intravasate, and spread within a bioreactor-perfused capillary network. Remarkably, dCTCs highly expressed epithelial-to-mesenchymal transition (EMT)-associated transcription factors (EMT-TFs), such as ZEB1, TWIST, and SOX9, which suggests that they undergo cellular reprogramming toward a less differentiated state by coopting the same epigenetic machinery used by carcinomas. Since YAP/TAZ and AXL tightly regulate the fate and plasticity of normal mesenchymal cells in response to microenvironmental cues, we explored whether these proteins contributed to OS metastatic potential using an isogenic pair of human OS cell lines that differ in AXL expression. We show that AXL inhibition significantly reduced the number of MG63.2 pulmonary metastases in murine models. Collectively, we present a laboratory-based method to detect and characterize a pure population of dCTCs, which provides a unique opportunity to study how OS cell fate and differentiation contributes to metastatic potential. Though the important step of clinical validation remains, our identification of AXL, ZEB1, and TWIST upregulation raises the tantalizing prospect that EMT-TF-directed therapies might expand the arsenal of therapies used to combat advanced-stage OS.